Steven Cohen Neurocrine Biosciences Inc Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 837,426 shares of NBIX stock, worth $113 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
837,426
Previous 1,391,970
39.84%
Holding current value
$113 Million
Previous $183 Million
37.03%
% of portfolio
0.29%
Previous 0.46%
Shares
22 transactions
Others Institutions Holding NBIX
# of Institutions
631Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.86 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.34 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$540 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$311 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$305 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...